Prevalence of metabolic syndrome and of symptoms of anxiety and depression in patients undergoing colonoscopy

M Marchi,S Alboni,A Fabbrizi,L Feltri,G Galli,A Guicciardi,S Mancini,G Mattei,A Minarini,D Perrone,G Rioli,L Roncucci,P Sena,S Ferrari

doi:10.1016/j.eurpsy.2017.02.236

Abstract

IntroductionMetabolic syndrome (MetS) is defined by metabolic and cardio-vascular impairments and is frequently associated with anxiety and depressive disorders. Both MetS and anxiety-depressive syndromes feature similar systemic inflammatory alterations. Inflammation of the large bowel is also a key factor for the development of colorectal cancer (CRC).ObjectiveTo measure the prevalence of MetS and symptoms of anxiety and depression among patients undergoing colonoscopy.MethodsCross-sectional study. Patients undergoing colonoscopy aged 40 or more, with negative history for neoplasia or inflammatory bowel disease, were enrolled. Data collected: colonoscopy outcome, presence/absence of MetS (IDF and ATP III criteria), presence/absence of depressive and anxiety symptoms assessed with HADS.ResultsThe sample was made up of 53 patients (female 24, 45.3%). Mean age was 60.66 ± 9.08. At least one adenoma was found to 23 patients (43.3%). Prevalence of MetS ranged from 34% to 36% (ATP III and IDF criteria, respectively). Prevalence of depressive and anxiety symptoms was 20% and 33%, respectively.ConclusionPrevalence of MetS, anxiety and depressive symptoms among patients undergoing colonoscopy was higher than in the general population.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Highlights

Cannabinoid hyperemesis syndrome (CHS), is characterized by recurrent episodes of severe nausea and intractable vomiting, preceded by chronic use of cannabis
Psychiatric morbidity is frequent in resistantepilepsy
We present three cases of patients who suffered from CHS and were admitted to emergency department

Summary

Conclusions

Olanzapine should be considered as an adequate treatment for CHS. Its availability in different routes of administration and its side effects profile could offer some benefits over haloperidol. Disclosure of interest The authors have not supplied their declaration of competing interest. An Italian observational study on subclinical cardiovascular risk factors and depressive symptomatology. A suggestion for the potential utility of a sinergic cardio-psychiatric perspective.

Introduction